Skip to main content

Table 1 Clinicopathologic characteristics of all 1396 patients with lymph node negative ER+/HER2- breast cancer and RS < 18 (all percentages within columns)

From: Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up

  RS 0–10 (n = 505) RS 11–17 (n = 891) Total (n = 1396)
RS: mean, median (range) 7, 8 (0–10) 14, 14 (11–17) 12, 12 (0–17)
Age at diagnosis
 Mean, median (range); years 58, 59 (25–84) 56, 55 (22–90) 57, 57 (22–90)
  < 40 years; n (%) 21 (4.2%) 42 (4.7%) 63 (4.5%)
  40–49 years; n (%) 111 (22%) 220 (24.7%) 331 (23.7%)
  ≥ 50 years; n (%) 373 (73.9%) 629 (70.6%) 1002 (71.8%)
Tumor size: mean, median (range); cm 1.31, 1.2 (0.4–5.8) 1.32, 1.2 (0.3–4.7) 1.32, 1.2 (0.3–5.8)
Multifocality; n (%) 123 (24.4%) 174 (19.5%) 297 (21.3%)
LVI; n (%) 90 (19.8%) 176 (17.8%) 266 (19.1%)
Local treatment; n (%)
 BCS only 15 (3%) 33 (3.7%) 48 (3.4%)
 BCS and radiation therapy 319 (63.2%) 611 (68.6%) 930 (66.6%)
 Total mastectomy 171 (33.9%) 243 (27.3%) 414 (29.7%)
 Total mastectomy and radiation therapy 0 4 (0.4%)b 4 (0.3%)b
Systemic therapy; n (%)
 Endocrine therapy alone 462 (91.5%) 722 (81%) 1184 (84.8%)
 Endocrine therapy and chemotherapya 22 (4.4%) 147 (16.5%)a 169 (12.1%)a
 No systemic therapy 21 (4.2%) 22 (2.5%) 43 (3.1%)
Median follow-up (range); months 52 (0.9–108.3) 52.2 (1–93) 52 (0.9–108.3)
LRR; n (%) 5 (1%) 8 (0.9%) 13 (0.9%)
  1. BCS breast conserving surgery, LRR locoregional recurrence, LVI lymphovascular invasion, RS recurrence score.
  2. aOne patient did not complete endocrine therapy
  3. bRadiation therapy following total mastectomy was given for ductal carcinoma in situ within 1 mm of the surgical margin (n = 3), and large (7 cm) tumor (n = 1)